Timeframe: 2024 – 2025 Study overview: Since the discovery in 2014 of the fusion gene (DNAJB1-PRKACA) that drives fibrolamellar carcinoma (FLC), a drug that would selectively inhibit or destroy the chimeric protein (DNAJ-PKAc) encoded by that gene has been considered a “holy grail” for FLC therapy. Such a drug must effectively target DNAJ-PKAc, while only …
Timeframe: 2024 – 2026 Goal: Determine if targeting CDK7 could be a useful treatment approach for FLC. Principal Investigator: Sean Ronnekleiv-Kelly, MD Study overview: Unregulated proliferation of cells is a hallmark of cancer. In other words, cancer cells continue to divide and increase in number when normal cells would stop dividing. A family of 20 …
Timeframe: 2024 – 2029 Goals: Assess the potential of a FLC therapeutic vaccine to prevent disease recurrence Principal Investigators: Juliane S. Walz, MD, CCU Translational Immunology, Department of Internal Medicine Study Background and Overview: Various research efforts supported by FCF over the last 6 years have shown that immunotherapy approaches can save FLC patients’ lives. …
Timeframe: 2024 – 2026 Goals: Streamline the collection, analysis and sharing of FLC data across institutions while supporting the broader goals of open science and collaborative research within the FLC research network Principal Investigators and Partners: FCF; Velsera; Praveen Sethupathy, PhD, Cornell University; Taran Gujral, PhD, Fred Hutchinson Cancer Center Study Overview: This study intends …